Johnson & Johnson released findings today that showed its single-shot COVID-19 vaccine was 66 percent effective (WaPo) in a global trial, while another U.S. firm, Novavax, said its vaccine was
nearly 90 percent effective (NYT) in an early analysis of a trial in the United Kingdom. Both vaccines were less effective against a new coronavirus variant that has spread in South Africa.
The emergence of coronavirus variants has complicated global vaccination efforts. Moderna and Pfizer-BioNTech, whose vaccines are already being used in several countries, reported this week that their vaccines are also less effective against the South African variant. Israel, which leads the world in vaccinations, hasn’t seen COVID-19 cases dramatically decline yet (Bloomberg), likely because of the transmission of variants. Additionally, many countries are struggling with vaccine shortages. The European Union is in a
dispute with AstraZeneca (BBC) after the company said last week that it had to send the bloc seventy-five million fewer doses than agreed upon. Some U.S. vaccination sites have had to
cancel thousands of appointments (AP) because of shortages. Many low-income countries haven’t even started vaccinating people yet, and recent reports have warned that it could take years for them to achieve herd immunity.